According to Vertex Pharmaceuticals's latest financial reports the company has a price-to-book ratio of 5.78.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 5.96 | 11.94% |
2022-12-31 | 5.33 | -3.71% |
2021-12-31 | 5.53 | -21.79% |
2020-12-31 | 7.07 | -24.08% |
2019-12-31 | 9.32 | -2.26% |
2018-12-31 | 9.53 | -48.63% |
2017-12-31 | 18.6 | 35.91% |
2016-12-31 | 13.7 | -51.82% |
2015-12-31 | 28.3 | 8.16% |
2014-12-31 | 26.2 | 104.6% |
2013-12-31 | 12.8 | 68.21% |
2012-12-31 | 7.61 | 2.05% |
2011-12-31 | 7.46 | -47.27% |
2010-12-31 | 14.1 | 81.01% |
2009-12-31 | 7.82 | -56.58% |
2008-12-31 | 18.0 | 58.2% |
2007-12-31 | 11.4 | 21.97% |
2006-12-31 | 9.33 | -25.45% |
2005-12-31 | 12.5 | -48.06% |
2004-12-31 | 24.1 | 475.21% |
2003-12-31 | 4.19 | 30.99% |
2002-12-31 | 3.20 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.11 | -11.72% | ๐บ๐ธ USA |
AbbVie ABBV | 28.0 | 384.76% | ๐บ๐ธ USA |
Gilead Sciences GILD | 3.63 | -37.31% | ๐บ๐ธ USA |
Merck MRK | 8.43 | 45.70% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 3.32 | -42.61% | ๐บ๐ธ USA |
Enanta Pharmaceuticals
ENTA | 1.46 | -74.78% | ๐บ๐ธ USA |